Google
HOOK — HOOKIPA PHARMA INC (Healthcare >> Biotechnology)
HOOK FAQ
What is HOOK's ROE?
HOOKIPA PHARMA INC reports a Return on Equity (ROE) of -195.24%.
What is HOOK's dividend yield?
HOOKIPA PHARMA INC offers a dividend yield of 0.00%.
What is HOOK's Deepscope Quality Score?
Deepscope rates HOOK's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HOOK?
Deepscope's AI Timing Score for HOOK is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HOOK belong to?
HOOKIPA PHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.09
Price
-0.05
(-4.39%)
Day Change
|
|
|---|
HOOK, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.09 |
| PBV / Sector |
0.50 / 4.48
GREAT
|
| Earning Per Share | -4.29 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
4111.547500000000
|
| Average 1W Daily Value |
2719.996000000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
62% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:13 |
| Symbol | HOOK |
| Name | HOOKIPA PHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.98 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.23 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 350 Fifth Avenue, New York, NY, United States, 10118
Phone: 431 890 6360
Website: https://www.hookipapharma.com
Employees: 82
Sector: Healthcare >> Biotechnology
Description: HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
